BellBrook Labs' Transcreener® HTS Assays Used to Explore New Ways to Attack Diseases
Two recent scientific publications show how Transcreener Assays for AMP/GMP and ADP detection enable high throughput screening (HTS) with emerging drug targets including chaperone ATPases, phosphodiesterases, fatty-acyl CoA synthetases and peptide ligases. The availability of robust HTS methods will facilitate the identification of selective inhibitors for these promising drug targets, an important first step in exploring new strategies to battle cancer, bacterial infections and other diseases.

BellBrook Labs Launches a New Transcreener HTS Enzyme Assay
The new Transcreener® GDP FI Assay is the only method available for direct detection of GDP with a positive fluorescence intensity signal. It allows screening of any GTPase, including small G proteins in the Ras and Rho families as well as Galpha proteins associated with GPCRs.

BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
The iuvo™ Chemotaxis Assay (http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html) Plate uses BellBrook’s proprietary microconduit array technology to provide quantitative measurements of neutrophil chemotaxis (http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html) in a defined gradient of chemoattractant that remains stable over the time period of the assay. Designed for use with existing liquid dispensing and high content analysis equipment, the 96-channel plate enables fully automated, image-based screening and profiling of compounds for chemotactic effects with very low cell and reagent consumption. ...